COMMUNIQUÉS West-GlobeNewswire

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines

28/10/2024 - 08:00

ViaNautis Bio Signs Strategic Collaboration Agreement with Lilly to leverage its polyNaut® platform to develop novel products delivering genetic medicines Multi-year collaboration will use ViaNautis’ non-immunogenic [...]

AAVantgarde Founder and Chief Scientific Officer, Professor Alberto Auricchio, is elected as President of the European Society of Gene and Cell Therapy

28/10/2024 - 08:00

MILAN, Oct. 28, 2024 (GLOBE NEWSWIRE) -- AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large [...]

BioSenic provides third quarter 2024 Business Update

28/10/2024 - 07:00

BioSenic provides third quarter 2024 Business Update BioSenic is actively seeking one or more new assets through a merger or acquisition process Mont-Saint-Guibert, Belgium, October 28, 2024, 7.00 am CEST – Regulated [...]

BioSenic fait le point sur ses activités du troisième trimestre 2024

28/10/2024 - 07:00

BioSenic fait le point sur ses activités du troisième trimestre 2024 BioSenic lance activement la recherche d'un ou de plusieurs nouveaux actifs par le biais d'un processus de fusion ou d'acquisition Mont-Saint-Guibert [...]

Philips delivers strong margin improvement; flat comparable sales due to further deteriorated demand in China; growth in rest of world

28/10/2024 - 07:00

October 28, 2024 Third-quarter highlights Group sales amounted to EUR 4.4 billion, with flat comparable sales growth Income from operations was EUR 337 million Adjusted EBITA margin increased by 160 basis points from 10 [...]

CORXEL and LENZ Therapeutics Announce Positive Topline Data from China Phase 3 Presbyopia Trial of LNZ100

28/10/2024 - 02:00

Primary endpoint was met with 74% of participants dosed with LNZ100 achieving three-lines or greater improvement at 3 hours post treatment，and maintaining their optimal distance visual acuity (i.e., not losing 5 or more [...]

Longeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons’ Society (CHSS) 51st Annual Meeting

27/10/2024 - 20:10

Oral presentation highlights findings that patients treated with Lomecel-B TM in ELPIS I, in an open-label follow-on study, experienced 5-year survival after stage 2 Glenn surgery of 100% with none requiring heart [...]

Phathom Pharmaceuticals to Present VOQUEZNA® Data at the American College of Gastroenterology (ACG) 2024 Annual Meeting

27/10/2024 - 17:00

FLORHAM PARK, N.J., Oct. 27, 2024 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) [...]

Positive Long-term Outcomes with HeartFlow FFRCT and Plaque Analysis Demonstrated in ADVANCE-DK Registry at TCT 2024

27/10/2024 - 13:15

— Data confirm the use of FFR CT and Plaque Analysis helps assess long-term risks, informing more personalized and effective treatment plans for patients with coronary artery disease -– FFR CT further validated in new [...]

Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024

27/10/2024 - 02:15

The detailed study results confirmed interim findings, showing stable kidney function and sustained treatment effect more than 18 months after the last dose of felzartamab Felzartamab, an investigational anti-CD38 [...]

Novartis oral Fabhalta® (iptacopan) sustained clinically meaningful results at one year in Phase III C3 glomerulopathy (C3G) trial

27/10/2024 - 01:50

New APPEAR-C3G data show Fabhalta sustained proteinuria reduction at 12 months 1 Upon Fabhalta initiation, improvement observed in estimated glomerular filtration rate (eGFR) slope – a key measure of kidney function – [...]

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

27/10/2024 - 01:30

Long-term improvements observed in the quartet of findings defining disease modification supports atacicept’s potential to prevent kidney failure in patients with IgAN; Long-term results from the ORIGIN Phase 2b study [...]

Celldex Announces Barzolvolimab Met All Primary and Secondary Endpoints with High Statistical Significance in Positive Phase 2 Study in Chronic Inducible Urticaria

26/10/2024 - 23:43

First to demonstrate clinical benefit in patients with chronic inducible urticaria (CIndU) in large, randomized, placebo-controlled study Favorable safety and tolerability Plan to advance CIndU into Phase 3 development [...]

Pivotal VALIANT Results Presented at Kidney Week Highlight Strength of Pegcetacoplan Treatment Effect in Patients with C3G / Primary IC-MPGN

26/10/2024 - 20:00

Statistically significant 68% (p<0.0001) proteinuria reduction compared to placebo, with reduction observed as early as Week 4 All secondary endpoints favored treatment with pegcetacoplan, including: Stabilized eGFR [...]

Travere Therapeutics Presents Data Reinforcing Clinical Benefit of FILSPARI® (Sparsentan) in IgAN and Late-Breaking Presentation in FSGS at ASN Kidney Week 2024

26/10/2024 - 13:01

Nearly 60% of patients with IgAN in the SPARTAN Study achieved complete remission when using FILSPARI as first-line treatment SPARTACUS Study, PROTECT open-label extension, and real-world evidence presentations [...]

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024

26/10/2024 - 09:30

Vivoryon Therapeutics N.V. Presents Outstanding Phase 2b Results of Varoglutamstat on Kidney Function at ASN Kidney Week 2024 Selected for late-breaking oral presentation at ASN kidney week, the world’s premier [...]

Tevogen Bio Provides Additional Guidance on Introduction of T Cell Therapy for Oncology and Specialty Care Therapeutic Areas

25/10/2024 - 23:34

WARREN, N.J., Oct. 25, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN ), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T [...]

ProQR Announces Closing of Underwritten Public Offering and Concurrent Private Placement

25/10/2024 - 22:45

LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 25, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a company dedicated to changing lives through transformative RNA therapies based on its [...]

Publication relating to transparency notifications

25/10/2024 - 22:30

REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), October 25, 2024 , 10:30 pm CET / 4:30 pm ET – In accordance with article 14 of the Act of 2 May 2007 on the [...]